Bispecific Antibodies Generate Excitement in Multiple Myeloma Treatment

Mohamad Mohty, MD, PhD, a professor of hematology at Saint-Antoine Hospital and University Pierre & Marie Curie, discusses the growing role of bispecific antibodies for the treatment of multiple myeloma, and highlights a study assessing a new bispecific antibody known as elranatamab (PF-06863135).

Elranatamab is a bispecific antibody targeting BCMA and CD3. The agent was evaluated in the MagnetisMM studies, including the phase 1 MagnetisMM-1 (NCT03269136), phase 1 MagnetisMM-2 (NCT04798586), phase 2 MagnetisMM-3 (NCT04649359), and phase 2 MagnetisMM-9 (NCT05014412) trials.

In this video, Mohty highlights the open-label, multicenter, non-randomized phase 2 MagnetisMM-3 which evaluated elranatamab monotherapy in patients with multiple myeloma who are refractory to at 1 or more proteasome inhibitors, 1 immunomodulatory drug, and 1 anti-CD38 monoclonal antibody.

In the study, investigators sought to determine whether or not elranatamab could provide clinical benefit in this patient population, and evaluated the primary end point of objective response rate (ORR) with secondary end points of duration of response, complete response rate, duration of complete response, progression-free survival, time to response, minimal residual disease negativity rate, safety, and pharmacokinetics.

TRANSCRIPTION:

0:08 | Of course, the science is very exciting and as expected, multiple myeloma is always on the podium. If I have to make a long story short, I would say that bispecifics are really the key word. This is about the so-called bispecific antibodies, or T-cell engagers, which are now proving to be highly effective in different hematological malignancies, especially in multiple myeloma. We are fortunate to have several of these agents now being developed.

1:00 | I myself was a co-author and participant to 1 of these studies. I must confess, it was a very popular study because the results were quite amazing. This is mainly about the results of the phase 2 study called MAGNETISMM-3, and this study tested the efficacy and safety of a new bispecific antibody called elranatamab.